Chitosan-based adjuvants

Molecular Vaccines: From Prophylaxis to Therapy - Volume 2

Volumn , Issue , 2014, Pages 623-631

  Gafvelin, Guro ^a   Grönlund, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84951124927     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-00978-0_13     Document Type: Chapter

References (44)

1. Nossal, G.J.: Vaccines of the future. Vaccine 29 Suppl 4, D111-D115 (2011). doi:10.1016/j.vaccine.2011.06.089. S0264-410X(11)00983-2 [pii]
2. Leroux-Roels, G.: Unmet needs in modern vaccinol-ogy: adjuvants to improve the immune response. Vaccine 28 Suppl 3, C25-C36 (2010). doi:10.1016/j. vaccine.2010.07.021. S0264-410X(10)01004-2 [pii]
3. McElhaney, J.E.: Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Rev. Vaccines 8, 593-606 (2009). doi:10.1586/erv.09.12
4. Schubert, C.: New vaccine tailored to the weakened elderly immune system. Nat. Med. 16, 137 (2010). doi:10.1038/nm0210-137a. nm0210-137a [pii]
5. Brewer, J.M., et al.: Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 163, 6448-6454 (1999). ji_v163n12p6448 [pii]
6. Mbow, M.L., De Gregorio, E., Valiante, N.M., Rappuoli, R.: New adjuvants for human vaccines. Curr. Opin. Immunol. 22, 411-416 (2010). doi:10.1016/j.coi.2010.04.004.S0952-7915(10)00068-3 [pii]
7. Schijns, V.E., Lavelle, E.C.: Trends in vaccine adjuvants. Expert Rev. Vaccines 10, 539-550 (2011). doi:10.1586/erv.11.21
8. Jabbal-Gill, I., Fisher, A.N., Rappuoli, R., Davis, S.S., Illum, L.: Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16, 2039-2046 (1998). S0264410X98000772 [pii]
9. Zaharoff, D.A., Rogers, C.J., Hance, K.W., Schlom, J., Greiner, J.W.: Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25, 2085-2094 (2007). doi: 10.1016/j.vaccine.2006.11.034. S0264-410X(06)01225-4 [pii]
10. Bonferoni, M.C., Sandri, G., Rossi, S., Ferrari, F., Caramella, C.: Chitosan and its salts for mucosal and transmucosal delivery. Expert Opin. Drug Deliv. 6, 923-939 (2009). doi:10.1517/17425240903114142
11. Sorlier, P., Denuziere, A., Viton, C., Domard, A.: Relation between the degree of acetylation and the electrostatic properties of chitin and chitosan. Biomacromolecules 2, 765-772 (2001)
12. Kumar, M.N., Muzzarelli, R.A., Muzzarelli, C., Sashiwa, H., Domb, A.J.: Chitosan chemistry and pharmaceutical perspectives. Chem. Rev. 104, 6017-6084 (2004). doi:10.1021/cr030441b
13. Illum, L., Farraj, N.F., Davis, S.S.: Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11, 1186-1189 (1994)
14. Alves, N.M., Mano, J.F.: Chitosan derivatives obtained by chemical modifications for biomedical and environmental applications. Int. J. Biol. Macromol. 43, 401-414 (2008). doi:10.1016/j. ijbiomac.2008.09.007. S0141-8130(08)00208-0 [pii]
15. Arca, H.C., Gunbeyaz, M., Senel, S.: Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 8, 937 (2009). doi:10.1586/erv.09.47
16. Jabbal-Gill, I., Watts, P., Smith, A.: Chitosan-based delivery systems for mucosal vaccines. Expert Opin. Drug Deliv. 9, 1051-1067 (2012). doi:10.1517/17425 247.2012.697455
17. Luppi, B., Bigucci, F., Cerchiara, T., Zecchi, V: Chitosan-based hydrogels for nasal drug delivery: from inserts to nanoparticles. Expert Opin. Drug Deliv. 7, 811-828 (2010). doi:10.1517/17425247.2010.495981
18. Gronlund, H., et al.: Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 107, 523-529 (2002). 1535 [pii]
19. Kamath, A.T., et al.: Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J. Immunol. 188, 4828-4837 (2012). doi:10.4049/jimmunol.1103183.jimmunol.1103183 [pii]
20. Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B., Rock, K.L.: Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. U.S.A. 90, 4942-4946 (1993)
21. Vila, A., Sanchez, A., Tobio, M., Calvo, P., Alonso, M.J.: Design of biodegradable particles for protein delivery. J. Control. Release 78, 15-24 (2002). S0168365901004862 [pii]
22. Vila, A., et al.: Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57, 123-131 (2004). S0939641103001620 [pii]
23. Amidi, M., et al.: Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J. Control. Release 111, 107-116 (2006). doi: 10.1016/j.jconrel.2005.11.014. S0168-3659(05)00652-8 [pii]
24. Saint-Lu, N., et al.: Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 64, 1003-1013 (2009). doi:10.1111/j. 1398-9995.2009.01945.x. ALL1945 [pii]
25. Porporatto, C., Bianco, I.D., Correa, S.G.: Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukoc. Biol. 78, 62-69 (2005). doi:10.1189/jlb.0904541. jlb.0904541 [pii]
26. Neimert-Andersson, T., et al.: Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a haemophilus influenzae type b glycoconjugate vaccine. Vaccine 29, 8965-8973 (2011). doi:10.1016/j.vac-cine.2011.09.041. S0264-410X(11)01447-2 [pii]
27. Ghendon, Y., et al.: Evaluation of properties of chito-san as an adjuvant for inactivated influenza vaccines administered parenterally. J. Med. Virol. 81, 494-506 (2009). doi:10.1002/jmv.21415
28. Lee, C.G., Da Silva, C.A., Lee, J.Y., Hartl, D., Elias, J.A.: Chitin regulation of immune responses: an old molecule with new roles. Curr. Opin. Immunol. 20, 684-689 (2008). doi: 10.1016/j.coi.2008.10.002. S0952-7915(08)00185-4 [pii]
29. Shibata, Y., Metzger, W.J., Myrvik, Q.N.: Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J. Immunol. 159, 2462-2467 (1997)
30. Da Silva, C.A., Hartl, D., Liu, W., Lee, C.G., Elias, J.A.: TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J. Immunol. 181, 4279-4286 (2008). 181/6/4279 [pii]
31. Da Silva, C.A., Pochard, P., Lee, C.G., Elias, J.A.: Chitin particles are multifaceted immune adjuvants. Am. J. Respir. Crit. Care Med. 182, 1482-1491 (2010). doi:10.1164/rccm.200912-1877OC. 200912-1877OC [pii]
32. Mora-Montes, H.M., et al.: Recognition and blocking of innate immunity cells by Candida albicans chitin. Infect. Immun. 79, 1961-1970 (2011). doi:10.1128/IAI.01282-10. IAI.01282-10 [pii]
33. Peluso, G., et al.: Chitosan-mediated stimulation of macrophage function. Biomaterials 15, 1215-1220 (1994)
34. Li, H., Willingham, S.B., Ting, J.P., Re, F.: Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17-21 (2008). 181/1/17 [pii]
35. Mori, A., et al.: The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chito-san does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur. J. Immunol. (2012). doi: 10.1002/eji.201242372
36. Hallander, H.O., Lepp, T., Ljungman, M., Netterlid, E., Andersson, M.: Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 118, 878-887 (2010). doi:10.1111/j.1600-0463.2010.02674.x
37. Muzzarelli, R.A.: Chitins and chitosans as immuno-adjuvants and non-allergenic drug carriers. Mar. Drugs 8, 292-312 (2010). doi:10.3390/md8020292
38. Mills, K.H., et al.: Protective levels of diphtherianeutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect. Immun. 71, 726732 (2003)
39. McNeela, E.A., et al.: Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22, 909-914 (2004). doi:10.1016/j. vaccine.2003.09.012. S0264410X03006728 [pii]
40. Read, R.C., et al.: Effective nasal influenza vaccine delivery using chitosan. Vaccine 23, 4367-4374 (2005). doi:10.1016/j.vaccine.2005.04.021. S0264-410X(05)00463-9 [pii]
41. Huo, Z., et al.: Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect. Immun. 73, 8256-8265 (2005). doi:10.1128/IAI.73.12.8256-8265.2005. 73/12/8256 [pii]
42. El-Kamary, S.S., et al.: Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202, 1649-1658 (2010). doi:10.1086/657087
43. Atmar, R.L., et al.: Norovirus vaccine against experimental human Norwalk Virus illness. N. Engl. J. Med. 365,2178-2187 (2011). doi:10.1056/NEJMoa1101245 Mucovac2. http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11679 (2012)
44. Li, X., et al.: Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients. Photochem. Photobiol. Sci. 10, 817-821 (2011). doi: 10.1039/c0pp00306a